Mayuko Nishihara

・Spearheaded the go-to-market strategy for a new perioperative lung cancer treatment in Japan, orchestrating a cross-functional team of 20. Conducted market research, segmentation, and positioning in alignment with the global brand strategy, resulting in full executive alignment during the senior pre-launch review. ・Mapped and assessed competitive dynamics by analyzing product profiles, competitors’ activities, and launch timelines to inform internal stakeholders and translate insights into actionable recommendations. ・Partnered with external vendors to design and implement end-to-end quantitative and qualitative research projects to assess treatment decision-making and brand perceptions of doctors. • Orchestrated cross-functional initiatives with medical, sales, and pathology teams to improve the sample testing pathway, and enhance collaboration between pathologists and pulmonologists through targeted educational webinars. • Formulated tailored promotional strategies based on PD-L1 expression levels in NSCLC, with a focused approach to address market competition in PD-L1-negative patients. Enabled the field team to engage pulmonologists in evidence-based discussions, resulting in a 3% market share increase within three months. ・Directed the development of 15 field-facing materials for HCPs and patients, ensuring regulatory alignment through Medical Legal Review. Collaborated closely with KOLs and an external agency to ensure scientific accuracy and engagement impact. ・Boosted lung cancer treatment market share by 5% within six months by conducting analytics using HCP behavioral data (rep visits, digital interactions) to optimize content and provide tailored recommendations to sales teams. ・Drove annual budget planning and tracking processes for over $3 million in promotional spending, consistently maintaining variance within 3% of the plan.

・Played a key role in driving the post-launch performance of Keytruda for breast cancer by enhancing field execution and aligning cross-functional strategies. • Orchestrated seamless omnichannel engagement by integrating digital and in-person touchpoints based on HCP behavioral insights, enhancing customer experience and contributing to increased share of voice in breast cancer. • Enabled >80% PD-L1 (22C3) testing availability within 6 months post-launch by supporting both in-house and outsourced diagnostics infrastructure. Drove adoption through Dr-to-Dr educational webinars and nationwide sharing of best practices, in collaboration with medical, sales, and pathology stakeholders. ・Developed and optimized KPI dashboards in collaboration with analytics teams, enabling real-time tracking of physician interactions and territory coverage. Provided consultative support to underperforming sales teams based on data insights, contributing to 150% sales target achievement in the post-launch period. ・Spearheaded the implementation of omnichannel engagement strategies, including the integration of third-party digital platforms during COVID-19, which led to a 50% increase in physician–rep interactions and improved engagement quality. ・Delivered monthly business performance reports and strategic recommendations for HQ and senior leadership, facilitating data-driven decision-making and continuous improvement. ・Acted as a bridge between HQ and field teams, collecting insights from sales representatives and transforming them into actionable feedback for brand and medical teams.

・Maximized sales in the assigned territory, achieving an annual revenue increase of $85,000; recognized with an award for ranking in the top 10% of sales representatives who consistently exceeded targets. ・Facilitated monthly online journal review meetings for sales team members across three prefectures, significantly enhancing disease knowledge and achieving 100% product knowledge among all team members.

• Leadership: Founded Hult Healthcare Industry Association of 40 members. Organized a healthcare conference with 100+ attendees in 2025 featuring medical experts from Blue Cross Blue Shield and Harvard. Topics included optimizing care, healthcare funding, and restoring trust. Achieved an NPS score of +65 from attendees. • Innovation: Developed and pitched a clinical trial matching app for underserved populations at the MIT Women’s Health AI Hackathon in 2025 and awarded as the “Most Scalable” team. • Analyzed a Starbucks-Tata joint venture case study, identifying key business challenges and investment opportunities; developed negotiation strategies and closed the deal by balancing both parties' goals, successfully achieving Tata's 51% ownership and establishing a sustainable strategic partnership.